HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


L’Oreal Hair-Relaxer Class Action A Far Cry From WEN, Or Next Plaintiff Payout?

This article was originally published in The Rose Sheet

Executive Summary

Putative class actions against L’Oreal alleging that a Soft Sheen-Carson hair relaxer causes hair loss and scalp irritation have been consolidated in New York’s Southern District. Similar to complaints targeting WEN in recent years, the L’Oreal suits cite “an inherent design and/or manufacturing defect,” but L’Oreal says it provides ample warning of risks on product packaging and the category represents known hazards.

You may also be interested in...

L’Oreal’s Gunslinging Counsel On Killing Amla Hair-Relaxer Class Action: ‘We Shot Every Bullet’

Gordon & Rees partner Peter Siachos for L’Oreal says the firm was “relentless” in its defense against a consolidated class action in New York’s Southern District concerning the SoftSheen Carson Amla Legend hair relaxer. Plaintiffs alleged the product is unreasonably dangerous and, at the same time, deceptively marketed as a gentler option than competing, lye-based offerings.

Global Corporate Insurer Projects Increased Liability For ‘Toxic Trio’ Use In Cosmetics

Allianz Global Corporate and Specialty raises liability concerns that could be relevant to cosmetics manufacturers still using “toxic trio” ingredients. The firm’s report is a signal at least that rampant US litigation for alleged false advertising and undeclared ingredient risks has reached the international insurance consciousness.

FDA Eyeing Study On Cosmetic Hair-Care/Hair-Loss Link

Interested parties capable of conducting in vivo and in vitro tests "to study alopecia that may be associated with the use of commercially available cosmetic hair products and individual ingredients in these products" must respond to FDA's Sources Sought Notice by Feb. 26.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts